Precision Biosciences Advances Duchenne Gene Therapy Program

Precision Biosciences is progressing its gene therapy candidate for Duchenne muscular dystrophy (DMD), with investor attention now turning to a key clinical data readout expected by the end of 2026. The company recently provided a clearer development timeline following regulatory clearance to begin human trials.

Regulatory Momentum and Clinical Timeline

The biotech firm’s program, PBGENE-DMD, has gained significant regulatory traction. The U.S. Food and Drug Administration (FDA) granted the therapy Fast Track designation in March, a status that can expedite the review process. This followed the February clearance to initiate a Phase 1/2 clinical trial, named FUNCTION-DMD.

During an investor event this Tuesday, management highlighted the program’s accelerated path. The therapeutic goal is to enable the production of a nearly full-length dystrophin protein, aiming to durably improve muscle function in patients. Preclinical data, according to the company, supports the potential for a long-lasting treatment effect.

Strong Financial Position Supports Pipeline

Precision Biosciences enters this critical clinical period from a position of financial strength. The company reported cash and equivalents of approximately $137.2 million as of December 31, 2025, which it states provides a cash runway sufficient to fund operations into 2028.

Should investors sell immediately? Or is it worth buying Precision Biosciences?

This liquidity is expected to cover major upcoming milestones for both its DMD and hepatitis B (HBV) programs. Additional financial highlights include a $7.5 million milestone payment received from TG Therapeutics and an extended patent protection for its PBGENE-HBV program, now lasting until November 2044.

Stock Pulls Back Following Significant Rally

Despite these operational advancements, the company’s shares experienced a pullback in today’s trading, declining over seven percent to €5.70. Market observers view this move as a natural correction following a substantial rally in recent weeks, during which the stock surged nearly 70% on a monthly basis.

Although the current price sits below its recent 52-week high of €7.45, it remains well above its 50-day moving average, suggesting the broader uptrend may still be intact.

Focus Shifts to Patient Recruitment and Data

The immediate focus for Precision Biosciences is patient enrollment for the FUNCTION-DMD trial. The company anticipates reporting initial safety and early efficacy data from multiple patients by the end of 2026. These results will be a crucial indicator of whether its differentiated gene-editing approach can effectively address the significant unmet medical need in Duchenne muscular dystrophy.